Autologous hematopoietic stem cell transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response'.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Outcomes of patients with hematological malignancies complicated with autoimmune diseases after allogeneic hematopoietic stem cell transplantation: A ten-year real-world study.Journal of translational internal medicine · 2026
   Article
2. Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis.Brain communications · 2023
   Article
3. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).Bone marrow transplantation · 2022
   Review
4. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.Journal of neurology · 2022
   Article
5. Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives.Biology · 2022
   Review
6. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE).Bone marrow transplantation · 2020
   Article
7. Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.Drugs · 2018
   Review
8. Emerging Cellular and Molecular Strategies for Enhancing Central Nervous System (CNS) Remyelination.Brain sciences · 2018
   Review
9. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases.Blood advances · 2017
   Article
10. Cell-based therapeutic strategies for multiple sclerosis.Brain : a journal of neurology · 2017
    Review
11. Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous haematopoietic stem cell transplantation.Clinical and experimental immunology · 2017
    Article
12. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.Current treatment options in neurology · 2013
    Article
13. Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis.Journal of neurology · 2013
    Article

Corrections and comments

• Comment on
  A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.2012

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as